Epizyme (EPZM) News Today → Have You Seen Elon’s New A.I. Device? (Picture Inside) (From InvestorPlace) (Ad) Free EPZM Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlinebluebird bio Inc BLUEmorningstar.com - November 1 at 9:33 AMCelgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pactthestreet.com - March 22 at 12:17 AMEpizyme (NASDAQ:EPZM) Earns Hold Rating from Analysts at StockNews.commarketbeat.com - October 3 at 2:17 AMAptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal - Nasdaqnasdaq.com - August 12 at 11:23 PMForm SC 14D9/A Epizyme, Inc. Filed by: Epizyme, Inc. - StreetInsider.comstreetinsider.com - August 12 at 6:23 PMmarketbeat.com - August 12 at 6:04 AMThe past five years for Epizyme (NASDAQ:EPZM) investors has not been profitablefinance.yahoo.com - August 10 at 11:59 AMEpizyme: Q2 Earnings Insights - Benzingabenzinga.com - August 9 at 4:52 PMEpizyme Reports Second Quarter 2022 Financial Results and Provides Business Update - Business Wirebusinesswire.com - August 9 at 4:52 PMEpizyme: Q2 Earnings Snapshotapnews.com - August 9 at 11:51 AMIpsen extends tender offer date in Epizyme deal to get US antitrust clearance - Seeking Alphaseekingalpha.com - August 5 at 11:49 AMIpsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022 - Business Wirebusinesswire.com - August 5 at 1:01 AMIpsen Delivers Strong H1 2022 Results and Upgrades Its Full-Year Guidance - Yahoo Financefinance.yahoo.com - July 28 at 4:38 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ONEM, EPZM, LION - PR Newswireprnewswire.com - July 26 at 5:35 PMShareholder Alert - The M&A Class Action Firm Continues Investigating the Merger - FSTX, EPZM, STCN, SIMO - Benzingabenzinga.com - July 16 at 12:23 PMSHAREHOLDER ALERT: Weiss Law Reminds RFP, ZEN, RDUS, and EPZM Shareholders About Its Ongoing Investigations - PR Newswireprnewswire.com - July 14 at 6:31 PMEPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM - Benzingabenzinga.com - July 14 at 2:42 AMForm SC 14D9 Epizyme, Inc. Filed by: Epizyme, Inc. - StreetInsider.comstreetinsider.com - July 13 at 1:32 AMEPIZYME ALERT: Bragar Eagel & Squire, PC Investigates Merger of EPZM and Encourages Investors to Contact the Firm - GuruFocus.comgurufocus.com - July 11 at 6:15 AMINVESTIGATION NOTICE: Halper Sadeh LLP Investigates RFP, VIVO, RADA, EPZM - GlobeNewswireglobenewswire.com - July 10 at 7:07 AMMoore Kuehn Encourages EPZM, RDUS, OBCI, and CNVY Investors to Contact Law Firm - PR Newswireprnewswire.com - July 6 at 5:23 PMEpizyme Acquisition By Ipsen: CVR Value (NASDAQ:EPZM) - Seeking Alphaseekingalpha.com - July 6 at 3:29 AMINVESTIGATION NOTICE: Halper Sadeh LLP Investigates ZEN, USAK, EPZM - PR Newswireprnewswire.com - July 5 at 10:29 PMEpizyme : Statement of Changes in Beneficial Ownership (Form 4) - Marketscreener.commarketscreener.com - July 5 at 5:24 PMEPIZYME ALERT: Bragar Eagel & Squire, PC Investigates Merger of EPZM and Encourages Investors to Contact the Firm - StreetInsider.comstreetinsider.com - July 1 at 3:55 AMEPIZYME ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of EPZM and Encourages Investors to Contact the Firmbenzinga.com - July 1 at 12:45 AMEPIZYME INVESTOR ALERT by the - GuruFocus.comgurufocus.com - June 29 at 6:37 PMIN BRIEF: BioPharma Credit says Epizyme investment to be prepaid | Financial News - London South Eastlse.co.uk - June 28 at 5:43 PMShareholder Alert - The M&A Class Action Firm Announces an Investigation of Epizyme, Inc. - EPZM - PR Newswireprnewswire.com - June 27 at 11:20 PMEpizyme, Inc. (NASDAQ:EPZM) Given Average Recommendation of "Hold" by Brokeragesmarketbeat.com - June 27 at 10:04 PMShareholder Alert - The M&A Class Action Firm Announces an Investigation of Epizyme, Inc. - EPZMprnewswire.com - June 27 at 9:42 PMEpizyme (NASDAQ:EPZM) Downgraded by Cowen to "Market Perform"marketbeat.com - June 27 at 9:07 PMWedbush Downgrades Epizyme to Neutral - Benzinga - Benzingabenzinga.com - June 27 at 6:20 PMThinking about buying stock in Epizyme, Acutus Medical, Agile Therapeutics, Axsome Therapeutics, or Evofem Biosciences? - PR Newswireprnewswire.com - June 27 at 6:20 PMEPZM Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Epizyme, Inc. Is Fair to Shareholders - Business Wirebusinesswire.com - June 27 at 6:20 PMEpizyme Shares Take Flight on Takeover by Ipsen >EPZM - MarketWatchmarketwatch.com - June 27 at 6:20 PMEpizyme shares soar 60% on acquisition newsfinance.yahoo.com - June 27 at 6:20 PMNorth American Morning Briefing : Hopes for Less Aggressive Fed Spur More Gains for Stocks - Marketscreener.commarketscreener.com - June 27 at 8:07 AMProsus, miners lift European shares to two-week high - Nasdaqnasdaq.com - June 27 at 8:07 AMEuropean Shares Set For Steady Opening As Inflation Worries Ease - Nasdaqnasdaq.com - June 27 at 3:06 AMFrance's Ipsen Launches Tender Offer to Purchase US Biopharmaceutical Epizyme - Marketscreener.commarketscreener.com - June 27 at 3:06 AMIpsen to Acquire Epizyme, Expanding Its Portfolio in Oncology - Business Wirebusinesswire.com - June 27 at 3:06 AMHUTCHMED Announces TAZVERIK® Approved to be Used in Hainan Pilot Zone in China - GuruFocus.comgurufocus.com - June 21 at 6:21 AMEpizyme's Return On Capital Employed Insights - Benzinga - Benzingabenzinga.com - June 9 at 1:43 PMWhy Is Epizyme (EPZM) Up 51.7% Since Last Earnings Report?finance.yahoo.com - June 9 at 1:43 PMHC Wainwright & Co. Maintains Buy on Epizyme, Lowers Price Target to $6 - Benzinga - Benzingabenzinga.com - June 3 at 7:22 AMEpizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting - Business Wirebusinesswire.com - June 2 at 9:18 PMEpizyme Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting - StreetInsider.comstreetinsider.com - June 2 at 4:18 PMEpizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting - Yahoo Financefinance.yahoo.com - June 2 at 11:15 AMEpizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meetingfinance.yahoo.com - June 2 at 11:15 AM Get Epizyme News Delivered to You Automatically Sign up to receive the latest news and ratings for EPZM and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon’s New A.I. Device is About to Shock the World (Ad)Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. EPZM Media Mentions By Week EPZM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EPZM News Sentiment▼0.220.34▲Average Medical News Sentiment EPZM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EPZM Articles This Week▼00▲EPZM Articles Average Week Get Epizyme News Delivered to You Automatically Sign up to receive the latest news and ratings for EPZM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PBYI News XBIT News XERS News VSTM News ME News TSVT News ACIU News NKTR News PYXS News ALDX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EPZM) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingCharles Payne’s Gift to Stock InvestorsUnstoppable ProsperityHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press4 coins to be the “Next Bitcoin”True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithElon Musk Secret Crypto Plot ExposedCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Epizyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
